Lanreotide combined with pembrolizumab led to stable disease with acceptable safety in nearly 40% of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs), according to results published at the virtual 2021 ASCO GI Cancers...
Lanreotide combined with pembrolizumab led to stable disease with acceptable safety in nearly 40% of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs), according to results published at the virtual 2021 ASCO GI Cancers...